Niagen Bioscience to Present at Lytham Partners Healthcare Investor Summit: Valuation and Key Risks

Niagen Bioscience (NAGE) is set to present at the 2nd Annual Lytham Partners Healthcare Investor Summit on January 15, 2026. The company's share price has declined 3.96% in the last 7 days and 14.96% in the last 90 days, but its 3-year total shareholder return is 244.81%. Niagen Bioscience is trading at $6.31 against an analyst price target of $15.80 and an indicated intrinsic discount of 61.5%. The company's narrative is undervalued, with a fair value of $16.04.